🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseQuit drinking AND started sema - liver is thanking me — looking for input

Quit drinking AND started sema - liver is thanking me — looking for input

Dr.LipidDallas Fri, Mar 22, 2024 at 4:23 AM 48 replies 2,428 viewsPage 1 of 10
This thread is more than 26 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.LipidDallas
VIP Member
2,678
14,567
Dec 2023
Dallas, TX
Mar 22, 2024 at 4:23 AM#1

This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.

Reduced interest in alcohol is one of the most consistently reported off-target effects, and the mechanism is plausibly the same reward-salience pathway that quiets food noise. The practical part people get wrong is that tolerance changes: less food in the stomach, faster gastric emptying of liquid relative to solids, and a smaller body mean the same two drinks land considerably harder than they used to.

Where I think it is weakest: the population was selected and supported in ways a real cohort is not, so I would read the effect size as a ceiling rather than an expectation.

What I am trying to establish is whether the change in tolerance is the smaller stomach, the smaller body, or something central, and whether it settles. If the honest answer is that nobody knows, that is a useful answer and I would rather have it.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
36 6pam_stl, wei_SG, cory_ATX and 33 others
Reply Quote Save Share Report
LipidDoc_ATL
Senior Member
1,123
5,678
Apr 2024
Atlanta, GA
Mar 22, 2024 at 4:52 AM#2
Dr.LipidDallas said:
Reduced interest in alcohol is one of the most consistently reported off-target effects, and the mechanism is plausibly the same reward-salience…

Agreed, and ALT falling is not the same as fibrosis improving. Enzymes are a crude proxy; FIB-4 or elastography is what tells you about the thing that matters.

I would rather be corrected than agreed with, if it comes to it.

35 5traveltech_sara, AttorneyGrant, DebRD_ATL and 32 others
Reply Quote Save Share Report
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
Mar 22, 2024 at 5:21 AM#3
Dr.LipidDallas said:
Reduced interest in alcohol is one of the most consistently reported off-target effects, and the mechanism is plausibly the same reward-salience…

I do not accept the framing. The question has been narrowed to the version that has a tidy answer, and the part that was dropped is the part the OP actually asked about.

34 4MikeNYC_runner and 31 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.LeslieOBGYN
Member
567
2,567
May 2024
Dallas, TX
Mar 22, 2024 at 5:50 AM#4

This one has a reasonably settled answer, so here it is. The liver data is among the strongest non-weight findings in the class. The semaglutide MASH programme reported a large advantage over placebo on MASH resolution, with a substantial minority also achieving fibrosis improvement — and fibrosis is the endpoint that predicts outcomes. Mechanistically it is reduced hepatic lipogenesis, increased fatty-acid oxidation, less hepatic inflammation, and possibly a direct effect on stellate-cell activation.

33 3NicoleRaleigh, james_edin, FranDenver and 30 others
Reply Quote Save Share Report
hank_denver
Member
278
1,234
Sep 2024
Denver, CO
Mar 22, 2024 at 8:32 AM#5
LipidDoc_ATL said:
Agreed, and ALT falling is not the same as fibrosis improving.

This is my experience too, for whatever a second data point is worth. Posting only so the count is not one.

Last edited: Mar 22, 2024 at 12:32 PM
32 2Dr.DermMIA, fiona_VT, denise_HTX and 29 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register